Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT

Takuji Okusaka; Kenji Ikeda; Masatoshi Kudo; Richard S. Finn; Shukui Qin; Kwang–Hyub Han; Ann‐Lii Cheng; Fabio Piscaglia; Masahiro Kobayashi; Max W. Sung; Minshan Chen; Lucjan Wyrwicz; Jung‐Hwan Yoon; Zhenggang Ren; Kalgi Mody; Corina E. Dutcus; Toshiyuki Tamai; Min Ren; Seiichi Hayato; Hiromitsu Kumada

doi:10.1007/s00535-021-01785-0

Related publications

Article2019

Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.

Takuji Okusaka, Kenji Ikeda, Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang–Hyub Han, Ann‐Lii Cheng, Fabio Piscaglia, Masahiro Kobayashi, Max W. Sung, Minshan Chen, Lucjan Wyrwicz, Jung‐Hwan Yoon, Zhenggang Ren, Daniel E. Stepan, Corina E. Dutcus, Toshiyuki Tamai, Min Ren, Seiichi Hayato, Hiromitsu Kumada

Article2019

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

Tatsuya Yamashita, Masatoshi Kudo, Kenji Ikeda, Namiki Izumi, Ryosuke Tateishi, Masafumi Ikeda, Hiroshi Aikata, Yasunori Kawaguchi, Yoshiyuki Wada, Kazushi Numata, Yoshitaka Inaba, Ryoko Kuromatsu, Masahiro Kobayashi, Takuji Okusaka, Toshiyuki Tamai, Chifumi Kitamura, Kenichi Saito, Katsuya Haruna, Kiwamu Okita, Hiromitsu Kumada

Article2016

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

Kenji Ikeda, Masatoshi Kudo, Seiji Kawazoe, Yukio Osaki, Masafumi Ikeda, Takuji Okusaka, Toshiyuki Tamai, Takuya Suzuki, Takashi Hisai, Seiichi Hayato, Kiwamu Okita, Hiromitsu Kumada

Article2021

Impact of bodyweight (BW)-based starting doses on safety and efficacy of lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC).

Takuji Okusaka, Masatoshi Kudo, Kenji Ikeda, Masafumi Ikeda, Kiwamu Okita, Toshiyuki Tamai, Min Ren, Kenichi Saito, Hiromitsu Kumada

Article2022

Characterization of tumor responses in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib in REFLECT.

Masatoshi Kudo, Shukui Qin, Fabio Piscaglia, Arndt Vogel, T.R. Jeffry Evans, Jennifer J. Knox, Carlos López, Zahra Ramji, Min Ren, Kalgi Mody, Richard S. Finn